Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Market Gems-Trading Strong Earnings Growth and Momentum -- Ignore unavailable to you. Want to Upgrade?

To: Jenna who wrote (5856)	3/5/2001 4:21:53 PM
From: 2MAR$	Respond to of 6445

REMEC Reports Fourth Quarter Fiscal 2001 Financial Results SAN DIEGO, March 5 /PRNewswire/ -- REMEC, Inc. (Nasdaq: REMC) today reported its financial results for its fourth quarter and fiscal year ended January 31, 2001. Net revenues for the fourth quarter of fiscal 2001 were $75.1 million, an increase of 49% over the $50.3 million reported in the same period of fiscal 2000. Net income for the fourth quarter of fiscal 2001 was $1.3 million, or $0.03 per share, compared with net income of $0.7 million, or $0.02 per share for the fourth quarter of fiscal 2000. Net revenues for the twelve months ended January 31, 2001, were $273.5 million, up 45% over the $189.2 million for the twelve months ended January 31,2000. Net income for the twelve months ended January 31, 2001 was $10.9 million, or $0.24 per share, compared with a net loss of $6.7 million, or $0.18 per share for the twelve months ended January 31, 2000. Historical earnings per share information has been adjusted to reflect the 50% stock dividend distributed on June 30, 2000. REMEC OVERVIEW REMEC is a leading designer and manufacturer of high frequency subsystems used in the transmission of voice, video and data traffic over wireless communications networks and in defense electronics applications. FOR MORE INFORMATION Management will be holding a conference call to discuss quarterly earnings today at 2 PM PST. To participate on the conference call, within the U.S., please call (800) 289-0436, confirmation code #424019. From outside the U.S., please call (913) 981-5507, confirmation code #424019, 10 minutes prior to the scheduled time of the call. You may access the conference call via a web broadcast on www.vcall.com. The rebroadcast number, which will play for seven days, is (888) 203-1112, confirmation code #424019.

To: Jenna who wrote (5856)	3/5/2001 4:31:23 PM
From: 2MAR$	Read Replies (1) \| Respond to of 6445

COR Therapeutics, Inc. Reports Significant Draw Down of Wholesaler Inventory; Business Editors/Health & Medical Writers SOUTH SAN FRANCISCO--(BW HealthWire)--March 5, 2001-- Lowers Guidance for Worldwide Q1 and Year-End 2001 INTEGRILIN(R) (Eptifibatide) Injection Sales COR Therapeutics, Inc. (NASDAQ: CORR) today indicated that while demand for INTEGRILIN(R) (eptifibatide) Injection remained strong, it was lowering its guidance for first quarter and year-end 2001 worldwide sales of INTEGRILIN(R) primarily due to unanticipated reductions of wholesaler inventory levels. COR also said that it now expects worldwide sales to be between $37 - $39 million for the first quarter of 2001 and between $245 - $260 million for the year 2001. Previous guidance was for worldwide sales to be between $250 - $270 million for the year 2001. COR also provided guidance that it would have a corresponding loss for the first quarter of $0.05 - $0.07 per share, as opposed to a consensus projection of $0.03 net income per share for the first quarter of 2001 and reduced its guidance for net income per share for 2001 to between $0.35 - $0.37, down from $0.40. COR stated that in-market sales shares remained in the high-20 percent range and patient market shares were holding firm in the mid-40 percent range. However, among the major wholesalers, average inventory levels have fallen to between 0.3 - 0.4 months, as opposed to 1.3 months at year-end 2000. COR will webcast a financial community conference call today, Monday, March 5, at 5:00 p.m. Eastern Standard Time (EST), or 2:00 p.m. Pacific Standard Time (PST). As part of the Company's efforts to ensure full disclosure to all parties, COR Therapeutics will host the webcast live on the Company's internet site as well as on internet conference-call provider VCall. The call will be led by Vaughn M. Kailian, President and Chief Executive Officer. To access the live call or the 5-day archive, please log onto corr.com. Alternatively, the webcast may be accessed by logging onto http:\\www.vcall.com/NASApp/VCall/EventPage?ID=69962. Please connect to either website at least 10 minutes prior to the conference call to ensure adequate time for any software download that may be needed to hear the live webcast. COR Therapeutics, Inc. is dedicated to the discovery, development, and commercialization of novel pharmaceutical products for the treatment and prevention of severe cardiovascular diseases. In addition to the historical information contained herein, this press release contains forward-looking statements that involve risks and uncertainties. Actual results may differ materially from the anticipated results discussed in such forward-looking statements, due to factors such as results of clinical trials with INTEGRILIN and other factors discussed in the Company's SEC reports, including, but not limited to, the Company's Report on Form 10-Q for the quarter ended September 30, 2000, and Report on Form 10-K for the year ended December 31, 1999. Forward-looking statements are based on current expectations and the Company does not intend to update such information to reflect later events or developments. --30--ac/ny* CONTACT: COR Therapeutics, Inc. Peter S. Roddy 650/244-6893 or Burns McClellan, Inc. Lisa Burns Jonathan M. Nugent 212/213-0006 KEYWORD: CALIFORNIA INDUSTRY KEYWORD: MEDICAL PHARMACEUTICAL BIOTECHNOLOGY Today's News On The Net - Business Wire's full file on the Internet with Hyperlinks to your home page. URL: businesswire.com * end of story *